A B S T R A C T An assay for the detection and quantitation of immune complexes is described. Experi Experimental immune complexes of bovine serum albumin-anti-bovine serum albumin were formed and tested by this assay, and immune complexes formed near antigen excess were best described by this technique.
INTRODUCTION
Immune complexes are recognized as important factors in the pathogenesis of various rheumatic and nonrheumatic diseases. Assays that detect circulating immune complexes have been developed and have been shown to be useful in the diagnosis and assessment of the clinical activities of these diseases. However, there appears to be significant variability in the results obtained by the various assays presently available (1) . The variability of results encountered with these assays included lack of specificity and sensitivity, unavailability and difficulties in maintenance of reference cell lines, and interference from substances such as endotoxins, DNA, and heparin. Therefore, these assays have remained experimental tools, and it has not been practical for clinical laboratories to perform these assays.
Immune complexes have been demonstrated on the surface of polymorphonuclear leukocytes (2, 3) . These complexes may produce inhibition of the killing of Escherichia coli by polymorphonuclear leukocytes (PMN)l (1) and impair neutrophil bactericidal activity of Staphylococcus aureus (4) . Using the concept that the microbicidal function of neutrophils will be depressed after interaction with immune complexes, we have used inhibition of PMN chemiluminescence to develop a simple and quantitative assay for the detection of immune complexes in human sera. In experiments using aggregated human gamma globulin, a direct correlation between percent inhibition in chemiluminescence and the amount of aggregated human gamma globulin exposed to the PMN was demonstrated, and a quantitative inhibition curve could be shown. Application of this method to sera specimens from patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and vasculitis demonstrated the presence of circulating immune complexes. METHODS 
Materials
Medium. RPMI 1640 without phenol red, supplemented with 100 U/ml of penicillin and 50 ,ug/ml of streptomycin (Associated Biomedic Systems, Inc., Buffalo, N. Y.) was used.
Complement source. Fresh normal human sera or pooled normal human sera stored at -700C and thawed once was used as a complement source in all experiments.
Complement determination. Total hemolytic complement (CH50) was determined by the method of Mayer (5) .
Zymosan preparation. Zymosan A (from S. cervisiae yeast, Sigma Chemical Co., St. Louis, Mo.) was suspended in RPMI 1640 to produce a stock solution of 10 mg/ml.
Antisera. The immunoglobulin (Ig)G fraction of rabbit antiserum to bovine serum albumin (BSA) was obtained from Pel-Freeze Biologicals, Inc., Rogers, Ark.
Leukocyte preparation. Blood was obtained from healthy adult donors by venipuncture. Leukocyte suspensions were prepared by standard techniques as described by Allen (6) , and adjusted to a final concentration of 5 x 106 cells/ml.
Preparation of aggregated human gamma globulin (AHG). Azide-free human IgG (Cohn fraction II, Pentex Biochemical, Kankakee, Ill.) was heat-aggregated in a water bath at 630C for 30 min. Each concentration of aggregates used in the experiments was prepared from a single batch and stored in 1-ml aliquots.
Sucrose density gradient ultracentrifugation. AHG was fractionated on a linear 10-40% sucrose density gradient in phosphate-buffered saline, pH 7.2. A 300-.ul sample (3 mg/ml) of AHG was layered on 5 ml of sucrose using a Buchler automatic density gradient maker (Buchler Instruments Inc., Fort Lee, N. J.). Ultracentrifugation was performed in an SW 50.1 rotor at 100,000 g for 16 h at 4°C in an L2 centrifuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.). Human hemoglobin, human 7S IgG, and human thyroglobulin were used as 4.5, 7, and 19S markers, respectively. 25 drop fractions were collected by piercing the cellulose nitrate tubes from below. Two 25-drop fractions were pooled and dialzyed overnight in phosphate-buffered saline, pH 7.2. These pools were then used in the chemiluminescence inhibition experiments.
Preparation ofimmune complexes. A quantitative precipitin curve was constructed for the BSA-anti-BSA system and equivalence determined. Increasing amounts of BSA (5-400 ,ug) were added to a constant amount of anti-BSA antibody (310 gg). These solutions were incubated for 1 h at 370C and overnight at 4°C. Precipitates formed were dissolved in 0.1 M NaOH, and the protein was quantitated by spectrophotometry at 280 nm. Supernates from antigen excess to antibody excess were used in the chemiluminescence inhibition assay.
PMN chemiluminescence (CL) inhibition assay for the detection of immune complexes in human sera. Sera (1000 Iul) to be assayed for immune complexes were incubated with centrifuged at 300 g for 5 min at 22°C, and the supernate decanted. The pellet was washed once with RPMI 1640, centrifuged at 300 g for 5 min and the supernate discarded.
The leukocyte pellet was resuspended in RPMI 1640 to a volume of 4.5 ml in a siliconized dark-adapted vial. CL was then measured in a scintillation spectrometer as described by Allen et al. (6, 7) .
Briefly, after completing two preliminary cycles to obtain background counts, 2.0 mg/ml of opsonized zymosan was added to each vial after a 1-min delay. Each vial was counted for 1 min, and counting was continued until a minimum of 10 cycles were completed. CL was measured with a Beckman scintillation spectrometer, model L230 (Beckman Instruments, Inc., Fullerton, Calif.) operated in the out-of-coincidence mode at room temperature (22°C). For continuous recording, the summation signal was fed into a Beckman Ratemeter and then to a Beckman Electronik Strip Chart Recorder. All additions to the siliconized vials were done under actinic light.
The CL, as total counts over a stated time interval, was calculated from measurements ofchemiluminescent intensity (counts per minute) at 10 different 1-min counting periods. The time between counts was the time required for one cycle of the sample train (6 min 
RESULTS
Inhibition of CL AHG. AHG, which possesses many properties of immune complexes (8) , was used in the initial experiments to determine its effects on CL. Increasing amounts of AHG (0.01-10 mg/ml) were incubated with NHS and 5 x 106 PMN/ml, and CL was measured after challenge with opsonized zymosan. Controls were PMN obtained from healthy donors, not incubated with AHG, but challenged with opsonized zymosan. Fig. 1 (Table III ).
In the sera of patients with SLE, the PMN CL inhibition assay detected immune complexes with a range of 23 to 1,200 ,ug AHG eq/ml. One patient had > 1,000 ,ug AHG eq/ml on two separate determinations. Total hemolytic complement was measured in these sera (Table IV) Col.) (9, 10) and the PMN CL inhibition assay (Table V) . Of 16 patients, 14 were positive by the Raji cell assay, and 12 were positive by the PMN CL inhibition assay. 11 sera were positive by both methods, whereas 2 were negative by both assays. Two sera were positive by the Raji cell assay and negative by the PMN CL inhibition assay. One patient was positive by the PMN CL inhibition assay, but negative with the Raji cell assay. Of the 11 patients with detectable immune complexes by both assays, the quantity was similar in 6.
DISCUSSION
The results of our study indicate that PMN can be used in a CL assay for the detection of immune complexes. Under normal conditions, phagocytosis of particles by neutrophils results in metabolic alterations such as increased hexose monophosphate shunt metabolism of glucose, activation of an oxidase system, and increased oxygen consumption. A portion of these metabolic reactions results in generation of electronically excited oxidation products. Relaxation of these products to ground state results in light emission or CL (7). This assay is based on a decrease in the CL response produced by neutrophils that have been preincubated with sera containing immune complexes and then challenged with opsonized zymosan. Previous investigators (11) (12) (13) (14) (15) (16) (17) have reported that normal PMN that were exposed to immune complexes, immunoglobulin aggregates, -or zymosan particles, released lysosomal enzymes. PMN membrane receptors were stimulated with initiation of biochemical events. These events occur with phagocytosis of the particles. However, they may occur independent of phagocytosis, as a consequence of leakage of enzymes into the extracellular environments when incompletely closed phagosomes fuse with lysosomal granules. Thus, in our assay, the decreased CL response produced by PMN preincubated with immune complexes may be secondary to a depressed microbicidal function of the PMN produced during their initial encounter with immune complexes.
To determine the size of complexes detected by the PMN CL inhibition assay, sucrose density gradient studies were performed using AHG. Sucrose density gradient fractionation of AHG demonstrated that intermediate-sized complexes and complexes 19S or greater were best detected by the PMN CL inhibition assay. Protein quantitation of each fraction demonstrated that inhibition was related to the activity of the complexes, and although there was some inhibition of the 7S fractions, these contained a significantly greater amount of protein. This is similar to the Raji cell (10) and monoclonal rheumatoid factor assays (18) which also detect immune complexes of intermediate and large molecular size.
Additional studies to determine the type of immune complexes detected demonstrated that conmplexes formed at equivalence to antigen excess produced the most inhibition in CL. This observation is similar to the fluid phase Clq binding assay which also detects immune complexes formed at equivalence to antigen excess. However, this feature is in contrast to the Raji cell and the solid phase Clq binding assays, which are more sensitive for the detection of immune complexes formed in antibody excess (19) .
The sensitivity of the PMN CL inhibition assay is the same as that of the Raji cell assay (10) . In our assay, 7 ,tg AHG equivalence, which is the sensitivity limit of the Raji cell assay, produced 15% inhibition in CL. The variation in CL produced by normal controls in our lab was 6+±4%. This assay is more sensitive than the Clq precipitation in gel (20) and radiolabeled Clq polyethylene glycol precipitation methods (21) which cannot detect AHG at concentrations <50 ug/ml. Thus the PMN CL inhibition assay offers sensitivity in detecting immune complexes that is similar to or greater than assays previously reported. (10, 21, (26) (27) (28) . Immune complexes in sera from 9/15 patients with SLE were detected by the PMN CL inhibition assay. This is less than the results reported using the Raji cell assay (10) . However, the Raji cell assay tested 92 serial monthly samples from 10 patients. This assay detected immune complexes in random single serum specimens from 15 patients. Our results are higher than those reported using monoclonal rheumatoid factor for the demonstration of immune complexes (18, 29) but similar to the results using staphylococci containing protein A (26) and the 1251-Clq binding assays (21, 27) in the detection of immune complexes. These differences may be secondary to the patient population studied, variations in assay sensitivities, differences in immune complex size and composition, and variation in reference curves.
Immune complexes have also been detected frequently in the sera and synovial fluid of patients with RA (18, (29) (30) (31) (32) . In this series of 30 patients with RA, 18/30 had immune complexes detected by the PMN CL inhibition assay. This is higher than previous results using monoclonal rheumatoid factor for the detection of immune complexes (18, 29) but lower than a recent report by a group using three different assays (32) (Clq binding, monoclonal rheumatoid factor, and Raji cell). Again, these percent differences may be secondary to the population studied or variability in the tests themselves or reference standards.
In the small group of patients with idiopathic vasculitis, immune complexes were detected in only one subject. This low percent is similar to the Raji cell assay (10) Antineutrophil antibodies, which have been reported in Felty's syndrome (35) , could possibly produce a false positive result in the PMN CL assay. Also, interference from circulating bacterial endotoxins could produce inhibition in CL. However, neither of these limitations have been tested using the PMN CL inhibition assay. Finally, as in previous assays, the PMN CL inhibition assay is unable to determine the antigen component of immune complexes.
At present, numerous assays are available for the detection of immune complexes in human sera. The PMN CL inhibition assay described in this report is simple, quantitative, reproducible, and readily performed. It is inexpensive and does not require cumbersome isolation of cells nor the use of radiolabeled substances. Further efforts are being directed at application of this assay in the detection of immune complexes in various other rheumatic and nonrheumatic diseases.
